Bank of New York Mellon
UNCY icon

Bank of New York Mellon’s Unicycive Therapeutics UNCY Stock Holding History

Bank of New York Mellon’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
+52,807
New +$390K ﹤0.01% 4081

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Bank of New York Mellon's UNCY Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Unicycive Therapeutics (UNCY) in Q2 2026: 52,807 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #4081 among its holdings.

24 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Bank of New York Mellon held 52,807 shares of Unicycive Therapeutics worth $248K as of Q2 2026.
  • Unicycive Therapeutics was a new Bank of New York Mellon position in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4081 holding.
  • 24 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.